Icotinib Hydrochloride - CAS 1204313-51-8

Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.

EGFR

Tyrosine Kinase/Adaptors, JAK/STAT signaling, Angiogenesis

1204254

0.9989

C22H22ClN3O4

427.88

Cl.C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1

-20°C

Ice Packs

Small Compound